The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.50
Bid: 45.00
Ask: 46.00
Change: -1.00 (-2.15%)
Spread: 1.00 (2.222%)
Open: 46.50
High: 45.50
Low: 45.00
Prev. Close: 46.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Avacta Partners With Integumen To Detect Covid-19 In Waste Water

Mon, 13th Jul 2020 11:23

(Alliance News) - Avacta PLC on Monday announced that it has entered into a collaboration with Integumen PLC to evaluate recently generated Affimer reagents that bind the SARS-COV-2 spike protein for the detection of Covid-19 in waste water.

Affimer reagents, a technology developed by drug and diagnostic tool developer Avacta, are a class of non-antibody binding proteins that have been engineered for a wide range of applications where antibodies and aptamers have limitations.

A reagent is a substance used, in this case for detection, for chemical analysis or other reactions.

Testing of the Affimer reagents will take place over the next few weeks after which validation of the sensors will be carried out using real SARS-COV-2 virus samples in a containment level 3 laboratory at the University of Aberdeen.

If these tests go well, it will enable the identification of Covid-19 hotspots in waste-water supplies as the virus can be found in the waste of most Covid-19 patients.

This can provide an early warning system in which authorities can be alerted through Integumen's alert system to prevent the spread of the disease to the wider community.

Avacta Chief Executive Alastair Smith said: "With the spread of Covid-19 continuing to accelerate globally, we are proud to work with partners like Integumen to provide our Affimer reagents for development on a range of platforms to combat the pandemic.

"This collaboration has the potential to deliver a product that will play a crucial role in the early detection of COVID-19 hotspots around the world."

Integumen is a scientific research and AI-as-a-service company focused on production and analysis of bacteria, virus and toxins.

Integumen and Avacta intend to enter a supply agreement for the supply of Affimers into Integumen's sensors upon the successful completion of the tests.

Avacta shares were down 0.2% at 119.25 pence each on Monday morning in London. Integumen shares were up 5.3% at 2.00p each.

Integumen's sensors will then be retrofitted into London-based water supply company Modern Water PLC's Microtox water contamination system units to detect Covid-19 in the water supply.

Modern Water Chief Executive Simon Humphrey said: "We are delighted to be in a position to have a distribution channel that can make the most of the roll-out of the real-time novel sensors for the detection of SARS-CoV-2.

"The completion of this evaluation which, if successful, could identify the level of infection in a community without the need for testing individuals is a very exciting breakthrough and we look forward to working with Integumen to make it happen."

Modern Water shares were up 11% at 2.04p each on Monday morning in London.

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
5 Apr 2023 12:51

Avacta doses first patient in higher-dose oncology cohort

(Sharecast News) - Life sciences company Avacta Group announced that it had dosed the first patient in the fifth cohort of the first-in-human phase one trial of its innovative oncology drug 'AVA6000' on Wednesday.

Read more
5 Apr 2023 12:12

Avacta doses first patient in fifth cohort of AVA6000 phase 1 study

(Alliance News) - Avacta Group PLC on Wednesday said the first patient has been dosed in the fifth cohort of the first-in-human phase 1 trial of AVA6000, a novel form of doxorubicin designed to improve its safety and therapeutic index.

Read more
27 Mar 2023 13:44

Avacta to present tumour medicine data at cancer research meeting

(Sharecast News) - Life science company Avacta Group announced on Monday that it will present a poster on its novel 'preCISION' medicine, 'AVA3996', at the American Association for Cancer Research (AACR) 2023 annual meeting in Florida on 16 April.

Read more
13 Mar 2023 12:18

SUMMARY: London listings with exposure to Silicon Valley Bank

(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
13 Mar 2023 10:08

Avacta has 'no relationship' with failed tech-focussed bank

(Sharecast News) - Life science company Avacta reassured the market on Monday, following the collapse of technology and science-focussed Silicon Valley Bank last week.

Read more
17 Jan 2023 17:16

Avacta reports positive progress in chemotherapy trial

(Sharecast News) - Oncology drug and diagnostics developer Avacta Group said in an update on Tuesday that 'AVA6000' was continuing to show a "very favourable" safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase-one clinical trial.

Read more
17 Jan 2023 16:23

TRADING UPDATES: hVIVO wins contract; Dev Clever cancels shares

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
8 Nov 2022 13:51

Avacta raises GBP64 million to finance Launch Diagnostics purchase

(Alliance News) - Avacta Group PLC on Tuesday closed its GBP2.0 million open offer of shares, bringing its total fundraise to GBP64.0 million.

Read more
18 Oct 2022 12:40

Avacta plans to raise GBP62 million; buys Launch Diagnostics

(Alliance News) - Avacta Group PLC on Tuesday announced a GBP62.0 million fundraise, which will be partially used to finance its acquisition of Launch Diagnostics Holdings Ltd for up GBP37 million.

Read more
18 Oct 2022 11:12

Avacta buying Launch Diagnostics for initial £24m

(Sharecast News) - Clinical-stage oncology drug company Avacta has conditionally agreed to acquire Launch Diagnostics, it announced on Tuesday, for an upfront cash consideration of £24m on a debt-free, cash-free basis.

Read more
29 Sep 2022 11:56

Avacta losses narrow as it progresses clinical programmes

(Sharecast News) - Clinical-stage oncology drug developer Avacta reported first-half revenue of £5.5m on Thursday, up from £1.5m year-on-year and from £2.9m for the full 2021 period.

Read more
29 Sep 2022 11:30

Avacta narrows loss, multiplies revenue thanks to Therapeutics divison

(Alliance News) - Avacta Group PLC on Thursday reported a narrowed interim loss as it multiplied its revenue significantly thanks to a strong performance from its Therapeutics division.

Read more
5 Sep 2022 11:07

AIM WINNERS & LOSERS: Avacta gets approval; Jubilee's Roan at capacity

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
5 Sep 2022 10:10

Avacta shares up as drug approved for soft tissue sarcoma treatment

(Alliance News) - Avacta Group PLC on Monday said it received approval for its AVA6000 for treatment of soft tissue sarcoma.

Read more
5 Sep 2022 07:16

Avacta's soft tissue sarcoma treatment gets FDA orphan drug designation

(Sharecast News) - Biotechnology company Avacta Group said on Monday that its soft tissue sarcoma treatment has been granted orphan drug designation by the US Food and Drug Administration.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.